Home | Cellectis

Time 2020-11-05 01:05:33

Web Name: Home | Cellectis

WebSite: http://www.cellectis.com

ID:105235

Keywords:

Home,Cellectis,

Description:

Cellectis leverages its leadership in gene editing through its flagship technology, TALEN , which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly available, off-the-shelf therapies. TALEN has been successfully used in the clinic to solve key challenges with allogeneic CAR T including protection from Graft vs. Host Disease, mitigation of rejection and enhanced safety via the integration of a suicide switch. Learn more "Off-the-shelf" immunotherapiesthat can work for the largest number of patients Cellectis gene-edits Chimeric Antigen Receptor (CAR) T-cells from healthy donors into off-the-shelf immunotherapy product candidates that are designed to work for the largest number of patients. It s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. This same technology, developed by Cellectis, could help in designing therapies for many other diseases. Learn more 20 years of innovation. 138 patent families. 107 granted patents and 568 applications. Global strategic partnerships with Allogene, Servier, and leading universities all over the world. Learn more Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST October 21, 2020 New York Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the third quarter of 2020 together with a business update on Thursday, November 5, 2020, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EST / 2:00 PM CET on Friday, November 6, 2020, prior to the open of the US market. October 16, 2020 New York (N.Y.) Cellectis S.A. (NASDAQ: CLLS EURONEXT GROWTH: ALCLS) announced today that its majority-owned subsidiary Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, has entered into definitive agreements with institutional investors for the purchase and sale of 3,750,000 shares of Calyxt s common stock, at a purchase price of $4.00 per share, in a registered direct offering. Cellectis subscribed to purchase 1,250,000 shares in the offering. Following the registered direct offering, Cellectis will own approximately 64.7% of Calyxt s outstanding shares of common stock. Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing July 21, 2020 New York (N.Y.) Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that Steve Doares, Ph.D., joins Cellectis from Biogen as Senior Vice President of US Manufacturing and Site Head of Raleigh manufacturing plant in NC. July 6, 2020 New York (N.Y.) Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced the publication of a new research paper released today in Frontiers in Bioengineering and Biotechnology. This article describes an innovative and easy-to-implement procedure which will streamline the manufacturing of allogeneic off-the-shelf CAR T-cell therapies. Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST Published on: October 21, 2020, 16:30 E.S.T. Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST October 21, 2020 New York Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the third quarter of 2020 together with a business update on Thursday, November 5, 2020, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EST / 2:00 PM CET on Friday, November 6, 2020, prior to the open of the US market. Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing Published on: July 21, 2020, 16:30 E.S.T. Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing July 21, 2020 New York (N.Y.) Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that Steve Doares, Ph.D., joins Cellectis from Biogen as Senior Vice President of US Manufacturing and Site Head of Raleigh manufacturing plant in NC. Cellectis Reports Clinical Hold Placed on MELANI-01 Study Published on: July 06, 2020, 16:50 E.S.T. Cellectis Reports Clinical Hold Placed on MELANI-01 Study July 6, 2020 New York (N.Y.) Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies Published on: June 25, 2020, 16:30 E.S.T. Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced the publication of a new research paper released today in Frontiers in Bioengineering and Biotechnology. This article describes an innovative and easy-to-implement procedure which will streamline the manufacturing of allogeneic off-the-shelf CAR T-cell therapies.

TAGS:Home Cellectis 

<<< Thank you for your visit >>>

Hot Websites